CaCU114OVERVIEW OF ACTIVITY
Hematologic oncology and related blood disorders are some of the most rapidly evolving fields in all of medicine. Results presented at major conferences from a plethora of ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care, the practicing hematologist-oncologist must be well informed of these advances. To bridge the gap between research and patient care, this issue of Cancer Conference Update uses one-on-one discussions with Drs Flowers, Fonseca, Kahl, Kantarjian and Talpaz about the integration of key data sets presented at the 2013 American Society of Hematology Annual Meeting into the practical management of a number of hematologic cancers and related blood disorders. LEARNING OBJECTIVES
ACCREDITATION STATEMENT
CME credit is no longer available for this issue CREDIT DESIGNATION STATEMENT CME credit is no longer available for this issue HOW TO USE THIS CME ACTIVITY CME credit is no longer available for this issue CONTENT VALIDATION AND DISCLOSURES FACULTY — Dr Kantarjian had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Fonseca — Consulting Agreements: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc; Contracted Research: Amgen Inc, Celgene Corporation. Dr Kahl — Advisory Committee: Celgene Corporation, Genentech BioOncology, Millennium: The Takeda Oncology Company, Roche Laboratories Inc; Contracted Research: Genentech BioOncology, Roche Laboratories Inc.
Dr Talpaz — Advisory Committee: ARIAD Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi; Consulting Agreement: Pfizer Inc; Contracted Research: Abbott Laboratories, ARIAD Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Pfizer Inc, Sanofi. Dr Flowers — Advisory Committee: Biogen Idec, Genentech BioOncology, Roche Laboratories Inc; Consulting Agreements: Algeta ASA, Celgene Corporation, OptumRx Inc; Contracted Research: Abbott Laboratories, Celgene Corporation, Millennium: The Takeda Oncology Company, Spectrum Pharmaceuticals Inc. EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors. This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology/Biogen Idec, Incyte Corporation and Onyx Pharmaceuticals Inc. Hardware/Software Requirements: Last review date: April 2014 |